MyVisionTest News Archive

Displaying news items tagged with VEGF Trap (More tags »)
SELECT PAGE
First <<  1 2   >> Last

Eylea
Jan 16, 2012
A phase 3 study of the efficacy of Eylea injections to treat neovascular AMD has shown sustained improvement in visual acuity at 96 weeks, Regeneron Pharmaceuticals and Bayer Healthcare announced in a press release. In the first year of the parallel VIEW 1 and VIEW 2 studies, patients received Eylea (aflibercept, Regeneron Pharmaceuticals)...

Full Article


Eylea
Jan 16, 2012
Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release. Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release...

Full Article


Eylea
Jan 8, 2012
The US Food and Drug Administration (FDA) approved aflibercept ophthalmic solution (Eylea, Regeneron Pharmaceuticals Inc) for the treatment of neovascular ("wet") age-related macular degeneration (AMD) in November 2011. "Eylea is an important new treatment option for adults with wet AMD," said Edward Cox of the FDA. "It is a potentially...

Full Article


VEGF-Trap
Sep 20, 2010
The GALILEO study has recently started phase 3 to assess the efficacy and safety of VEGF Trap-Eye in the treatment of macular edema in central retinal vein occlusion, a speaker announced here. "Enrollment of 117 patients from 10 countries was completed in July," Frank Holz, MD, said at the Euretina meeting here preceding the European Society...

Full Article


VEGF-Trap
Nov 24, 2009
The CLEAR-IT 2 trial was a phase 2 study of the safety and efficacy of VEGF Trap-Eye in patients with neovascular age-related macular degeneration (AMD). An extension of the CLEAR-IT 2 trial followed patients from the original trial. Below are the results of the initial CLEAR-IT 2 as well as 6-month data from the extension stage. CLEAR-IT 2...

Full Article


Intravitreal injection
Nov 18, 2009
Vascular endothelial growth factor (VEGF) ligands and their receptors are essential for development and for a wide variety of physiologic functions through adulthood, including visual function. Given the ubiquitous physiologic role of VEGF, evaluation of potential safety risks associated with nonspecific inhibition of VEGF-A and other VEGF-related...

Full Article


VEGF-Trap
Oct 26, 2009
Data from the extension study of VEGF-Trap suggest clinically significant improvements in vision with low dosing burden and a favorable safety profile, according to a speaker at the American Academy of Ophthalmology meeting. In the CLEAR-IT 2 extension study, 117 patients were followed with as-needed therapy with VEGF-Trap (Aflibercept,...

Full Article


Age-related Macular Degeneration
Oct 22, 2009
Although the optimal dosing of anti-VEGF therapy remains unknown, pharmacokinetics of the two most popular agents suggest that adjusting the current dosing strategies may better serve patient needs. Head-to-head trials of Lucentis (ranibizumab) and Avastin (bevacizumab) should help steer future treatment decisions, Philip J. Rosenfeld, MD, PhD,...

Full Article


Regeneron Pharmaceuticals
Aug 13, 2009
Regeneron Pharmaceuticals announced that the first patient has been enrolled in the Phase 3 program of VEGF Trap-Eye for the treatment of central retinal vein occlusion (CRVO), a leading cause of blindness in adults. Regeneron also announced that enrollment in the Phase 2 DA VINCI study of VEGF Trap-Eye in diabetic macular edema (DME) has been...

Full Article


Regeneron Pharmaceuticals
May 22, 2009
VEGF Trap-Eye is entering a new phase 3 program designed to evaluate the safety and efficacy of the agent for treating patients with central retinal vein occlusion, according to a press release. Expected to begin late in 2009, the phase 3 program will consist of two identical multinational 1-year clinical trials. The first, called COPERNICUS (...

Full Article


SELECT PAGE
First <<  1 2   >> Last
Most Popular
Less - past - More